NEW YORK — Evotec and Celmatix said today that they have formed a drug-discovery partnership focused on prevalent but underserved women's reproductive health conditions including polycystic ovary syndrome, endometriosis, and infertility.
Under the terms of the alliance, Hamburg, Germany-based Evotec will be responsible for medicinal chemistry and in vitro and in vivo pharmacology activities. Celmatix — which recently launched a division to discover therapeutics for women's health indications including reproductive disorders — will contribute to drug-discovery efforts using its Reproductive Atlas platform, which combines biological annotations from peer-reviewed literature with genomic data associated with lifestyle, diet, environment, and reproductive outcomes.
Additional terms were not disclosed.
"Through combining our vast datasets and deep expertise in women's health with Evotec's proven experience in therapeutic discovery, we are poised to catalyse real change and finally provide women therapies they deserve," Piraye Yurttas Beim, founder and CEO of New York City-based Celmatix, said in a statement.